LEGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LE

Mkt Cap

$3.59B

Volume

2.68M

Next Earnings

November 11th

Loading chart

LE

LEGNLegend Biotech Corporation American Depositary Shares

LEGN

Pay with—

Available Balance0.00

LE

Mkt Cap

$3.85B

Volume

2.68M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Why Is Legend Biotech Stock Falling Thursday?Legend Biotech (LEGN) stock fell 7.52% in premarket trading Thursday after the cell therapy company announced an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million. The decline comes despite the company's strong market position and analyst Buy rating with a $58.57 price target, though recent earnings showed a wider-than-expected loss and revenue slightly below consensus.Benzinga · Jun 18, 2026

Legend Biotech Corporation Announces Pricing of Public OfferingLegend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.GlobeNewswire Inc. · Jun 18, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaLegend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.GlobeNewswire Inc. · Jun 14, 2026

Why Legend Biotech Stock Crushed the Market on MondayLegend Biotech (LEGN) surged 18% on Monday following bullish analyst updates from H.C. Wainwright and RBC Capital. The rally was partly inspired by Eli Lilly's $7 billion acquisition of Kelonia Therapeutics, a CAR-T therapy developer similar to Legend. Analysts highlighted Legend's promising pipeline programs, including encouraging progress on its CD19/CD20 dual-targeted therapy.The Motley Fool · Apr 20, 2026

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million SharesSuvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk management decision following the dramatic stock appreciation rather than a loss of conviction in the company's fundamentals.The Motley Fool · Dec 23, 2025

Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myelomaA study of CARVYKTI® demonstrated lasting treatment-free remissions in 80% of standard-risk multiple myeloma patients when used as early as second-line therapy, with improved immune fitness potentially correlating with longer progression-free survival.GlobeNewswire Inc. · Dec 6, 2025

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & TradeLegend Biotech was awarded Foreign Investor of the Year at the 2025 Flanders International Business Awards for its €165 million investment with Johnson & Johnson to expand cell therapy manufacturing in Ghent, Belgium, growing from 2 to over 1,000 employees.GlobeNewswire Inc. · Nov 27, 2025

Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.GlobeNewswire Inc. · Nov 17, 2025

Legend Biotech Reports First Quarter 2025 Results and Recent HighlightsLegend Biotech reported strong Q1 2025 results, with CARVYKTI® net trade sales of $369 million and over 6,000 patients treated to date. The company received positive regulatory updates, expanded manufacturing capacity, and maintained a strong cash position of $1 billion, which is expected to provide financial runway into Q2 2026.GlobeNewswire Inc. · May 13, 2025

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen PharmaceuticalsThe article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.GlobeNewswire Inc. · Nov 6, 2024

to start trading

LE

LEGNLegend Biotech Corporation American Depositary Shares

LEGN

Pay with—

Available Balance0.00

Your PositionYou don't own any LEGN yet.

Related Tickers

Earnings